Key facts
- It has raised $11.1M.
- Notable investors include Global Incubator Network.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for LoopLab Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for LoopLab Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LoopLab Bio
Developer of therapeutic biotechnology designed to address immunological diseases. The company's platform combines expertise in immunology, molecular biology, and protein engineering, applies methods to rebalance immune system activity, induces tolerance to prevent harmful immune cell responses, maintains natural defenses, and incorporates advanced therapeutic strategies, enabling healthcare providers, research institutions, and pharmaceutical companies to develop treatments that improve disease management, enhance patient outcomes, and expand options for comprehensive immunological care.
- Sector
- Healthcare
- HQ
- Vienna, Austria
- Founded
- 2023
- Employees
- 17
- Website
- looplab.bio/
- Ownership
- Privately Held (backing)
LoopLab Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LoopLab Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LoopLab Bio in its N-PORT filings yet. We sweep new filings monthly.